News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on AdAlta.
RELATED STOCKHEAD STORIES
Health & Biotech
Countdown on to AdAlta trial results as biotech advances partner discussions
Health & Biotech
AdAlta advancing partnering programs as AD-214 participants receive final dose
Stockhead TV
What’s in store for 2024: AdAlta
Experts
Money Talks: Keep an eye on these tasty precious metal and biotech plays in 2024
Stockhead TV
Long Shortz with AdAlta: How the company has potentially broken the malaria life cycle
News
In Case You Missed It: New niobium and REE projects plus scaffold distribution deals
Health & Biotech
‘World first’: AdAlta’s i-body platform a breakthrough for malaria treatment
News
In Case You Missed It: Heavy mineral sands, a biotech takeover and some gold
Health & Biotech
AdAlta on track for trial readout in Q1 2024 after $1.65m cap raise
Health & Biotech
‘Best place we’ve ever been’: AdAlta looks to monetise lead asset in 2024
News
In Case You Missed It: UAE agricultural deliveries and some Swedish lithium
Health & Biotech
AdAlta’s latest results bolster safety profile and dose selection for primary asset, enhancing partnering, reducing Phase 2 trial risks
Health & Biotech
ASX Health Stocks: Painchek’s Europe patent accepted; and HeraMed signs deal with Telstra Health
News
Closing Bell: ASX has best week ever… or at least since everything crashed last month. So… wait… damn you Friday!
News
Market Highlights: Wall Street slips, common mistakes in stock trading, and 5 ASX small caps to watch today
Health & Biotech
ASX Health Stocks: Mesoblast crashes 54pc after FDA says it needs more data for approval
News
